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Non-Toxic Glycosylated Gold Nanoparticle-Amphotericin B
Conjugates Reduce Biofilms and Intracellular Burden of
Fungi and Parasites
Chandradhish Ghosh, Silvia Varela-Aramburu, Hassan E. Eldesouky, Sharareh Salehi
Hossainy, Mohamed N. Seleem, Toni Aebischer, and Peter H. Seeberger*
Infections by intracellular pathogens cause significant morbidity and mortality
due to lack of efficient drug delivery. Amphotericin B, currently used to treat
leishmaniasis and cryptococcosis, is very toxic and cannot eradicate
intracellular Cryptococcus neoformans (C. neoformans). Glycosylated gold
nanoparticles are water dispersible and biocompatible with very little toxicity.
While amphotericin B is insoluble in water at neutral pH, conjugates of
amphotericin B and ultra-small gold nanoparticles (AuNP) are better
dispersible in water. Amphotericin B conjugated glycosylated gold
nanoparticles (AmpoB@AuNP) are more efficacious in treating both
extracellular and intracellular forms of Leishmania mexicana (L. mexicana)
than amphotericin B alone. In addition, AmpoB@AuNP are effective in
reducing C. neoformans biofilms by 80% and intracellular C. neoformans
burden by >90%. Furthermore, AmpoB@AuNP are not haemolytic at
50 µg mL−1 and are significantly less toxic to murine macrophages than
amphotericin B. Ultra-small AuNPs are attractive delivery agents to treat
intracellular infections and AmpoB@AuNP may be useful for treating
C. neoformans infections in immunocompromised patients.
1. Introduction
Infectious diseases are a major contributor to human morbidity
and mortality.[1] The utility of antimicrobial agents decreases as
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pathogens develop resistance against many
frontline drugs.[2] Pathogens that survive
withinmammalian cells are particularly dif-
ficult to treat.[3] Pathogens such as Leishma-
nia spp. and C. neoformans evade phagocy-
tosis before residing and replicating within
macrophages that are an important part of
the human immune system.[3,4] Treatment
of these diseases is challenging as drugs
have to enter macrophages before they can
exert their anti-infective action.[3,5] Delivery
agents that will facilitate the internalization
of drugs into specific mammalian cells may
be a solution to this problem.
The facultative intracellular pathogen C.
neoformans causes life-threatening menin-
gitis in patients suffering from AIDS, can-
cer, autoimmune diseases, and is respon-
sible for around 600 000 deaths globally.[6]
Upon inhalation, Cryptococcus sp. spores
are engulfed by the alveolar macrophages
wherein they survive and replicate in
mature phagolysosomes. C. neoformans
disseminates to other organs including the central nervous
system.[6a] After crossing the blood brain barrier C. neofor-
mans can form biofilms, called cryptococcomas that protects
them fromhost immune defences and antimicrobial therapy.[6a,7]
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Therapy against biofilms and intracellular forms ofC. neoformans
is ineffective or drastically reduced.[8,7b] The complications as-
sociated with C. neoformans infections are a challenging unmet
medical need that is being addressed via different paths.[9]
Leishmaniasis, a parasitic tropical disease with high mortality
in its most severe form is caused by parasites that exist in two
different forms within their host.[10] Extracellular forms called
promastigotes are transferred by a sand-fly bite to the host upon
a blood meal. These promastigotes are engulfed by phagocytes,
in particular, macrophages where they transform to amastig-
otes and multiply by division. As the disease develops, amastig-
otes released from host cells are propagated as more and more
macrophages become infected. Alternatively, amastigote infected
cells are taken up by the sand fly upon biting an infected host, to
enter into a new life cycle.
Amphotericin B, the drug used to treat both cryptococcosis
and in particular, the severe mucocutaneous and visceral forms
of leishmaniasis is poorly water-soluble and quite toxic.[10b] Li-
posomal formulations of amphotericin B such as AmBisome
have reduced its toxicity, but the storage of liposomal formula-
tions is more difficult and costly.[11] To overcome some of these
shortcomings, amphotericin B, has been chemically modified,
conjugated to polymers,[12] dendrimers,[13] carbon nanotubes,[14]
and other nanoparticles.[15] Attempts to improve the solubility
of amphotericin B have been made but the toxicity has not
been addressed.[16] Recent attempts toward understanding tox-
icity caused by amphotericin B has led to it being used for other
diseases as well.[17] Nevertheless, orally available nanoformula-
tions of amphotericin B remain elusive.[18] More importantly, the
drug fails to reduce intracellular infections of C. neoformans and
their biofilms effectively.
The optical properties of inert and biocompatible[19] gold
nanoparticles[20] can be exploited for diagnostic and other
applications.[21] Nanoparticulate gold is not toxic to animals[22]
and glycosylated-gold nanoparticles[23] are non-toxic and water-
soluble.[24] The presence of the sugar not only improves the dis-
persibility in water but also facilitates further functionalization.
Gold nanoparticles can bind to cysteine-rich surface proteins of
pathogens due to the affinity for gold to thiols for targeted drug
delivery.[25] Here, we show that conjugation of amphotericin B to
glycogold nanoparticles renders the drug water dispersible and
lowers its toxicity. A significant improvement in drug activity was
observed against L. mexicana and C. neoformans. Unlike ampho-
tericin B, the conjugate was effective in reducing biofilms and
intracellular burden of C. neoformans.
2. Results and Discussion
2.1. Synthesis and Characterization
The parent gold nanoparticles were prepared bymodifying a pub-
lished protocol.[24] Aurochloric acid was reduced and capped with
thioglucose to yield glyco-gold nanoparticles <5 nm according to
transmission electron microscopy (TEM) (Figure S1A, Support-
ing Information). Dynamic light scattering (DLS) revealed hydro-
dynamic radii of the particles between 10 and 20 nm. The zeta
potential for the nanoparticles was determined to be −30 mV
(Figure S1B,C, Supporting Information). The thioglucose likely
undergoes partial oxidation during the process to yield COOH
groups that could be used for further functionalization.
Modification on the mycosamine nitrogen leads to less
toxic amphotericin B derivatives without adversely affect-
ing the activity.[26] Thus, it was reasoned that conjuga-
tion of amphothericin B to glycogold nanoparticles via the
amine group may reduce the toxicity of the drug. The car-
boxylic acid moieties on the nanoparticles will impart charge
to the conjugate and allow for more water molecules to
interact with the nanoparticle for better aqueous disper-
sion. The carboxylic acid groups of the naked glycogold
nanoparticles were activated by sonicating AuNP solution with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) for five minutes before a
solution of amphotericin B in dimethyl sulfoxide (DMSO) was
added and sonicated for 2 h (Scheme 1). The resultant solution
was subjected to dialysis in milliQ water overnight to obtain the
amphotericin B-conjugated nanoparticles (AmpoB@AuNP) that
were further purified by passing them through a 0.45 µm fil-
ter. This solution was characterized using ultraviolet absorption
(UV), infrared spectroscopy (IR), DLS, TEM, and atomic force
microscopy (AFM).
Amphotericin B is soluble in DMSO and not in water
(Figure 1A). In comparison, the dispersion of AmpoB@AuNP in
water is clear (Figure 1A). UV spectroscopy is an important tool
to characterize amphotericin B as it absorbs sharply at 365, 384,
and 408 nm in DMSO (Figure 1B). Amphotericin B is not water-
soluble, so itsUV absorption spectrum inwater was not recorded.
The suspension of naked gold nanoparticles inwater absorbs very
little (Figure 1B). The AmpoB@AuNP dispersion in water ab-
sorbs at around 325 nm. Both Ambiosome and Fungizone are
known to absorb very strongly at 322 nm, which is indicative of
the dimeric aggregates of amphotericin B (Figure S1, Supporting
Information).[27] In case of AmpoB@AuNP, although the maxi-
mum is at 325 nm, other small humps (from 375 to 425 nm) indi-
cated presence of other aggregates (Figure S1, Supporting Infor-
mation). Similar observations were made with super-aggregates
of amphotericin B.[28] However, lyophilization of the water dis-
persion followed by resuspension in DMSO shows the charac-
teristic peaks of amphotericin B allowing for quantification of
the drug conjugated to the nanoparticles (explained below). IR
of AmpoB@AuNP reveals distinct peaks at 1654 and 1574 cm−1
that represent the carbonyl stretch and N─H bending respec-
tively, convincingly proving the existence of the amide bonds ex-
pected from the reaction (Figure 1C). A shoulder at around 1700
cm−1 may reflect the free carboxylic acid group of amphotericin
B. DLS was used to determine the hydrodynamic radii of the Am-
poB@AuNP suspension. (Figure 1D). It was observed that the hy-
drodynamic radius of the particles increases by 20–30 to ≈45 nm
in comparison to the naked gold nanoparticles (≈15 nm, Figure
S2B, Supporting Information). The nanoparticles have a 𝜁 poten-
tial of the nanoparticles remain similar both before (−30mV) and
after conjugation (−28 mV) confirming their stability in water
(Figure 1E and Figure S2C, Supporting Information). TEM anal-
ysis of AmpoB@AuNP confirms that the size of the gold clus-
ters is <5 nm (Figure 1F). However, it does not show the actual
size of the nanoparticles but only the gold core. AFM was used
to visualize and determine the actual particle size. The size of
the AmpoB@AuNP varied from 6 to 8 nm, (Figure 1G), while
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Scheme 1. Synthesis of the amphotericin B—nanoparticle conjugates. (EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide; Sulfo-NHS: N-
hydroxysulfosuccinamide; AmpoB: Amphotericin B. Only one AmpoB in the conjugated form is shown for clarity.)
Figure 1. Characterization of AmpoB@AuNP. A) Amphotericin B is soluble in DMSO and insoluble in water, while Ampob@AuNP result in a clear
solution. B) UV absorption of the different materials used in the study. AuNP absorbs slightly. For AmpoB in DMSO three distinct peaks are observed at
365, 384, and 408 nm. AmpoB@AuNP do not show signature peaks but have strong absorbance around 340 nm while the same sample in DMSO shows
distinct features. C) IR spectra of AmpoB@AuNP shows prominent amide bond peaks at 1654 and 1574 cm−1 that are absent in case of Amphotericin
B and AuNP. D) DLS measurements indicate that the hydrodynamic radii AmpoB@AuNP are mostly ≈45 nm. E) Zeta potential of AmpoB@AuNP is
−28 mV (colored lines represent triplicates in 1D and 1E). F) TEM images of AmpoB@AuNP show the core structure of the gold nanoparticles to be
<5 nm (scale bar 20 nm). G) AFM image of AmpoB@AuNP reveals its size to be 6–8 nm.
that of the unconjugated AuNP was 2–3 nm (Figure 1GS2, Sup-
porting Information). This is also clarified by the line scan of the
particles (Figure S3, Supporting Information). The synthetic pro-
cess is reproducible as the nanoparticles maintain similar size,
surface, and optical characteristics for each batch. The samples
can be stored at 4–8 °C for more than 6 months without signifi-
cant change in stability or physical properties (based onUV, TEM,
DLS, and Zeta potential).
2.2. Quantification of Amphotericin B and Gold Present in the
Solution
UV spectroscopy was employed to calculate the amount of
amphotericin B present in the suspension. First, the absorbance
of amphotericin B was recorded in presence or absence of
AuNP (Figure S4A, Supporting Information). Since there was
no change in the absorbance it was concluded that the molar
absorptivity of amphotericin B in DMSO remained unchanged
in presence and absence of AuNP (Figure S3A, Supporting
Information). Then different concentrations of amphotericin B
(in DMSO) were recorded and plotted to create a standard curve
(Figure S4B,C, Supporting Information). Since the absorption
spectrum of AmpoB@AuNP in water (Figure 1B) could not be
correlated with that of Amphotericin B in DMSO (Figure 1B),
AmpoB@AuNP solutions were first lyophilized and then re-
suspended in an equal volume of DMSO. The absorbance of
this solution was correlated with the concentration of ampho-
tericin B based on the standard curve. (Figure S3, Supporting
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Figure 2. A) Activity of AmpoB@AuNP against metacylcic promastigotes of Leishmania sp. Error bars represent standard deviation values. B) Uptake of
ATTO@AuNP nanoparticles by macrophages analyzed by flow cytometry. The shift in the intensity of the fluorescence signal indicates that ATTO@AuNP
cells were internalized. The same number of events was recorded. C) Activity against intramacrophage L.mexicana (DSred). Macrophage cells are stained
with DAPI and the infected cells are recognized by the red fluorescence of the parasites. Amphotericin B is partly active at 0.35 µg mL−1 but completely
active at 0.7 µg mL−1. AmpoB@AuNP are partly active at 0.13 µg mL−1 while completely active at 0.25 µg mL−1. AuNP do not show inhibition. Error
bars represent standard deviation values for triplicates performed using OriginPro 2020b (OriginLab, Northampton, Massachusetts, USA).
Information). The concentration of gold (Au) in the samples was
measured using inductively coupled plasma-optical emission
spectroscopy. The average ratio between the concentration of am-
photericin B and the concentration of gold in the Ampob@AuNP
solution (based amount present in µg mL−1) was determined to
be 2.5. That corresponds to ≈30 amphotericin B molecules per
nanoparticle based on the calculations published previously. For
ease of comparison, all activity values are reported in terms of
concentration of amphotericinAmphotericin B present in the
solution of AmpoB@AuNP as opposed to the concentration of
nanoparticles present.
2.3. Activity against Extracellular Leishmania sp.
The nanoparticles were checked for activity against the extracel-
lular form of L. major and L. mexicana parasites and compared
to the parent drug. Complete inhibition of cell growth was ob-
served at 250 ng mL−1 of AmpoB@AuNP against both L. mexi-
cana and L. major (Figure 2A). The IC50 of AmpoB@AuNP was
measured at ≈0.1 µg mL−1 against L. major and ≈0.13 µg mL−1
against L. mexicana while free drug displayed values between 0.7
and 1 µg mL−1 (Figure 2A).
2.4. Intracellular Uptake of Nanoparticles
To study intracellular uptake, AuNPs functionalized with a dye
ATTO647N was incubated with macrophages. After washing any
surface bound nanoparticles, internalization using flow cytome-
try was measured. From the flow cytometry analysis, a clear uni-
form shift in fluorescence intensity of ATTO@AuNP treated cells
was observed in comparison to untreated cells confirming the
internalization of the particles within macrophages (Figure 2B).
Internalization was also observed previously in RBCs.[25]
2.5. Activity against Intracellular L. mexicana
The genetically modified L. mexicana parasite fluoresces red and
can be easily observed under a fluorescence microscope. Upon
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Table 1. Summary of antifungal activity.
Fungal isolates MIC range [µg mL−1]
Fluconazole Amphotericin B AmpoB@AuNP
Aspergillus sp. ⇒128 2 1
Candida sp. 0.5–>128 0.5–2 0.5–2
Cryptococcus sp. 4–32 1–2 0.5
Unconjugated AuNP was not active.
staining the macrophage nuclei with DAPI, the parasites inside
the cell can be easily identified. In the negative control, most of
the macrophages (stained blue) contain parasites (stained red)
(Figure 2C). Amphotericin B was less effective at 0.35 µg mL−1
while no parasites were observed at 0.7 µg mL−1. The IC50 of
AmpoB@AuNP against extracellular parasites was determined at
0.13 µg mL−1, such that treatment with 0.125 µg mL−1, resulted
in some parasite-infected macrophages. At 0.25 µg mL−1 of Am-
poB@AuNP, no parasites were found within the macrophages
illustrating that passive internalization and targeted delivery en-
hances drug efficacy. Encouraged by these results, the activity of
AmpoB@AuNP against fungi was evaluated next.
2.6. Activity against Planktonic Fungi
The minimum inhibitory concentrations (MIC) of amphotericin
B, unconjugated gold nanoparticle (AuNP), and AmpoB@AuNP
were determined against Aspergillus sp., Candida sp., and Crypto-
coccus sp to test whether the nanoparticle formulation enhanced
the antifungal activity of amphotericin B (Table 1 and Table S1,
Supporting Information). The compounds were tested against
three clinical isolates of Aspergillus sp. and revealed that Am-
poB@AuNP is twice as active (MIC = 1 µg mL−1) as the parent
drug (MIC = 2 µg mL−1) (Table 1). AuNP were not active against
the pathogens. Activity againstCandida spp.was tested using four
strains ofC. albicans, five strains of the new emergingmultidrug-
resistant C. auris, four strains of C. glabrata, two strains of C. kru-
sei, two strains of C. parapsilosis and C. tropicalis. AmpoB@AuNP
were as active as amphotericin B against all the strains ofCandida
except C. albicans ATCC 10231, where it was twice more potent
than the drug alone.
Next, the compounds were evaluated against C. gattii and C.
neoformans, the causative agents of cryptococcosis, and cryptococ-
cal meningitis (Table 2). AmpoB@AuNP were twice more potent
than amphotericin B against the four clinical isolates of C. gattii.
The MIC of AmpoB@AuNP was 0.5 µg mL−1 while the unconju-
gated drug was active at 1 µg mL−1. The two clinical isolates of C.
neoformans that are resistant to fluconazole require 2 µg mL−1 of
amphotericin B for activity while AmpoB@AuNP remained ac-
tive at 0.5 µg mL−1. AmpoB@AuNP were equally or more potent
than free amphotericin B against all the fungi that we tested.
2.7. Kinetics of Killing/Antifungal Activity
To assess whether conjugation of amphotericin B to gold
nanoparticles alters the rate of killing, the kill kinetics of C. neo-
Table 2. Antifungal activity against Cryptococcus species.
Fungal isolate MIC [µg mL−1]
Fluconazole Amphotericin B AmpoB@AuNP
C. gattii NR-43208 8 1 0.5
C. gattii NR-43209 16 1 0.5
C. gattii NR-43210 16 1 0.5
C. gattii NR-43213 8 1 0.5
C. neoformans NR-41291 16 2 0.5
C. neoformans NR-41295 32 2 0.5
C. neoformans NR-41298 4 1 0.5
C. neoformans NR-48767 4 1 0.5
Unconjugated AuNP was not active.
formans NR41298 with AmpoB@AuNP was determined. The ki-
netics of the fungicidal activity of AmpoB@AuNP and free am-
photericin B were the same at 2 µg mL−1 as fungal burden was
reduced by five logarithmic scales within 2 h. Free AuNP had no
effect on the cells (Figure 3A).
2.8. Activity against C. Neoformans NR-41298 Biofilms
C. neoformans notoriously forms and survives within biofilms,
a.k.a. cryptococcomas that are recalcitrant to antifungals and
the human immune response. Proteins associated with C. neo-
formans virulence and biofilms contain cysteine-rich regions.[29]
Thus, multivalent presentation of the drug and interaction with
gold might be able to destroy fungal biofilms more effectively
than the unbound drug. Thus, we subjected preformed biofilms
of C. neoformans to treatment with AmpoB@AuNP and the free
drug. Metabolic activity of the biofilms after 24 h indicated that
even at concentrations as low as 0.25 µg mL−1, AmpoB@AuNP
were able to reduce the burden by 50% while free amphotericin
B was not very active at this concentration (Figure S5, Support-
ing Information). At higher concentrations, the activity of both
AmpoB@AuNP and Amphotericin B increased. When treated
with 0.5 µg mL−1 of AmpoB@AuNP, the metabolic activity of
the biofilms was reduced by 75% to further emphasize the po-
tency of AmpoB@AuNP against biofilm infections of C. neofor-
mans (Figure 3B). This observation was confirmed by confocal
microscopy (Figure S6, Supporting Information). Amphotericin
B treated biofilms were stained green (SYTO-9) only and not red
(PI), like that negative control and unconjugated gold nanoparti-
cles. On the contrary, significant population of AmpoB@AuNP
treated cells were stained red indicative of death (Figure S6, Sup-
porting Information).
2.9. Activity against Intracellular C. neoformans
C. neoformans survive and replicate within immune cells. This
form of the pathogen is extremely difficult to treat as no dedi-
cated therapeutic is available. Clinically used antifungals are not
active against the intracellular form of the pathogen.[8,30] Since
AmpoB@AuNP were able to clear L. mexicana residing within
Adv. Therap. 2021, 4, 2000293 2000293 (5 of 8) © 2021 The Authors. Advanced Therapeutics published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advtherap.com
Figure 3. A) Time-kill analysis of Amphotericin B nanoparticles (AmpoB@AuNP) and free Amphotericin B (at 2 µg mL−1) against C. neoformans NR-
41298 over a 48 h incubation period at 35 °C. DMSO, AuNP served as controls. B) Biofilm eradicating activity of Amphotericin B nanoparticles (Am-
poB@AuNP) against C. neoformansNR-41298 biofilm evaluated with the XTT assay over a 24-h period. The percent metabolic activity for each treatment
was calculated relative to untreated wells. Error bars represent standard deviation values. C) Activity against intracellular C. neoformans. Fungal burden of
J774mousemacrophages infected with C. neoformansNR-41298, was reduced drastically when treated with AmpoB@AuNP from 8 µg/mL. Amphotericin
B is not active. The reduction observed here is partly because of its toxic effect on J774.1 cells. (*) denotes the statistical difference between amphotericin
nanoparticles and the untreated control group whereas hash (#) indicates a statistical significance between the amphotericin nanoparticles and the free
amphotericin. The statistical significance was assessed with one-way ANOVA, with post hoc Dunnet’s multiple comparisons test (p < 0.05), utilizing
GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
macrophages we hypothesized that the intracellular C. neofor-
mans can be eradicated by AmpoB@AuNP. At 8 µg mL−1 Am-
poB@AuNP were able to reduce 75% of the intracellular burden
of C. neoformans (Figure 3C). AmpoB@AuNP (16 µg mL−1) re-
duced the fungal burden by more than 90%. The less significant
reduction in case of amphotericin B at 8 and 16 µg mL−1 was
attributed to its cytotoxic effect on the cells.
2.10. Toxicity
Finally, the toxicity of AmpoB@AuNP against mammalian cells
was evaluated. The toxicity was evaluated against erythrocytes
and the two different murine macrophages used for leishmanial
studies and fungal studies (J774.1) respectively (Figure 4A–C).
Incubation with freshly isolated erythrocytes for 1h revealed that
AmpoB@AuNP do not induce visible haemolysis (Figure 4A)
even till 64 µg mL−1. Amphotericin B, on the other hand,
induces haemolysis at concentrations as low as 6.2 µg mL−1
(Figure 4B).
Then, the toxicity of the compounds was evaluated in murine
macrophages that served as hosts for L. mexicana. LIVE/DEAD
staining with a mixture of fluorescein diacetate (FDA) and
propidium iodide (PI) was used to determine the toxicity. FDA
is a non-fluorescent, cell-permeant dye that is converted to
fluorescein intracellularly by esterases expressed by viable cells.
The resultant green fluorescence is an indicator of cell-viability.
In contrast, PI is non-permeant across cells and stains the nu-
cleus of membrane-compromised cells. When untreated murine
macrophages were stained with a mixture of dyes, only green
fluorescence was observed (Figure 4C). Upon treatment with
Triton X, the cells were compromised allowing PI to stain them
red. Similarly, at 16 µg mL−1, amphotericin B was toxic to the
cells (mostly red fluorescence is observed) while AmpoB@AuNP
were not toxic even at 32 µg mL−1 (only green fluorescence
was observed). Then, viability of J774.1 cells (the hosts for C.
neoformans), when treated with different nanoparticles at varying
concentrations, was quantified using MTS assay (Figure 4D).
Amphotericin B was toxic at concentrations as low as 2 µg mL−1.
At 8 µg mL−1 amphotericin B treated cells, only 50% of the
macrophages remain viable and at 16 µgmL−1 almost 80% of the
cells are lysed. In comparison, upon treatment with 32 µg mL−1
of AmpoB@AuNP, more than 70% of the cells are viable. No
toxicity is observed at 16 µg mL−1 of AmpoB@AuNP. Thus,
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Figure 4. Toxicity of different Amphotericin B formulations. A) Visual representation of haemolysis. 1) Negative control (not haemolytic) 2) Am-
poB@AuNP are not haemolytic at concentrations of 64 µg mL−1. 3) Unbound Amphotericin B shows haemolysis even at 12.5 µg mL−1 4) Naked
AuNP show no hemolysis and 5) Triton X (positive control) 100% haemolysis. B) Percentage of haemolysis of Amphotericin B and AmpoB@AuNP
at different concentrations. C). LIVE/DEAD staining to determine toxicity of AmpoB@AuNP against murine macrophages. Fluorescence microscopy
images of macrophage cells after treatment with or without Triton X, Amphotericin B, and AmpoB@AuNP. Staining was performed with fluorescein
diacetate (stains intact cells green) and propidium iodide (stains dead cells red). Scale bar 10 µm. D) Toxicity analysis of murine macrophage cells
(J774.1) exposed to AmpoB@AuNP, free Amphotericin B, and AuNP for 24 h. Data represent percent viable cells after exposure to the tested treatments
at a concentration range 0.25 to 32 µg mL−1 using the MTS assay. Dimethyl sulfoxide (DMSO) was used as a negative control. Error bars represent
standard deviation values for triplicates performed using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
AmpoB@AuNP have no associated toxicity against mammalian
cells at therapeutically relevant concentrations.
3. Conclusion
Multivalent presentation of amphotericin B on ultrasmall
nanoparticles renders the formulation dispersible in aqueous
media and no loss of activity due to aggregation was observed.
Macrophage entry was facilitated due to improved cellular up-
take, and less amphotericin B was required for activity while the
toxicity was reduced. Although amphotericin B is used as a drug
to treat cryptococcosis, it cannot clear biofilms and intracellular
forms of C. neoformans. The nanogold formulation inhibits all
forms of cryptococcal infections at concentrations that are not
toxic to the mammalian cells. These glycogold conjugates may
be useful for the treatment of intracellular C. neoformans.
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